US LNG exports surge but will buyers in China turn up?
FORT LEE, N.J. - Nuvectis Pharma, Inc. (NASDAQ:NVCT), a clinical-stage biopharmaceutical company with a market capitalization of $234.5 million, announced Tuesday the completion of a drug-drug interaction (DDI) study for its cancer drug candidate NXP900, classifying it as a weak inhibitor of the CYP3A enzyme. According to InvestingPro analysis, the company currently appears overvalued, despite showing strong financial stability with a current ratio of 3.28.
The clinical study in 14 healthy volunteers showed NXP900 increased the concentration of midazolam, a known CYP3A substrate, by less than two-fold. This classification supports NXP900’s potential use in combination with market-leading epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) inhibitors for non-small cell lung cancer treatment. The company’s development efforts come amid strong market performance, with InvestingPro data showing a 27.2% price return over the past six months.
No serious adverse events were reported in the study, with mild to moderate diarrhea and non-infection related increases in white blood cell counts being the most common side effects.
Ron Bentsur, Chairman and CEO of Nuvectis, stated the company plans to advance NXP900 into a Phase 1b program in the coming weeks following completion of the current Phase 1a dose escalation study in patients with advanced cancers.
The Phase 1b program will evaluate NXP900 both as a single agent and in combination with leading EGFR and ALK drugs in patients whose cancers are expected to be sensitive to SRC/YES1 inhibition.
NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases with a mechanism that inhibits both catalytic and scaffolding functions of the SRC kinase.
Nuvectis is also developing NXP800, an oral GCN2 activator currently in Phase 1b trials for platinum-resistant, ARID1a-mutated ovarian carcinoma and cholangiocarcinoma.
The information in this article is based on a company press release statement. For comprehensive financial analysis and additional insights, including 8 more exclusive InvestingPro Tips for Nuvectis Pharma, visit InvestingPro.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.